VICOR Study-High Frequency Chest Wall Oscillations (HFCWO) in Patients With Acute Respiratory Failure and Hypersecretion

Last updated: February 25, 2023
Sponsor: Raffaele Scala
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lung Injury

Acute Respiratory Distress Syndrome (Ards)

Respiratory Failure

Treatment

N/A

Clinical Study ID

NCT05751707
VICOR2
  • Ages > 18
  • All Genders

Study Summary

The study aims to evaluates if the treatment with HFCWO Via The Vest® Airway Clearance System, in addition to standard care in critically ill patients admitted in the Respiratory Intensive Care Unit for acute respiratory failure or acute on chronic respiratory failure and unable to manage secretions, could primarily prevent the need for bronchoscopy, and secondarily shorten duration of non invasive respiratory therapy, shorten length of stay and reduce mortality.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of acute respiratory failure (ARF) or acute on chronic respiratory failure (including patients having home oxygen therapy, HFNC, NIV) both hypercapnic ARF (PaCO2 > 45 mmHg; PaO2/FiO2 <300) or hypoxaemic (PaCO2 <45 mmHg; PaO2/FiO2 <300);
  • Informed consent from patient or legal tutor;
  • Accessory respiratory muscles use;
  • Respiratory rate above 25 apm;
  • Use of non invasive respiratory therapy (NIRT) NIV+/-HFNC or HFNC alone since RICUadmission
  • Kelly neurological index ≤ 3
  • Excessive airway mucus secretion (clinical evaluation asking the patient to cough) andinability to efficiently remove secretions (evaluated with the Cough Peak Flow (CPF)measurement. A CPF under 270 Lpm is highly suggestive of inadequate cough whichprevent the patient from adequately manage and remove airway secretions.
  • Cough score < 3: in the case of inability to perform CPF measurement due to poorpatient collaboration, cough adequacy will be evaluated by a respiratory physiotherapywith a semiquantitative score ("Cough score") based on the measurement of sputumvolume produced after coughing three times (1 point: less than 2 mL, 2 points: 2-6 mL, 3 points: more than 6 mL).

Exclusion

Exclusion Criteria:

  • Patient unwillingness or incapability to provide informed consent
  • Need for subcontinuous NIV(more than 20 hours per day)
  • Kelly neurological index >3
  • Cardiac arrest
  • Severe haemodynamic instability (more than two amines required);
  • acute coronary syndrome;
  • Psychomotor agitation unresponsive to analgo-sedation (RASS> 1)
  • Contraindications to HFCWO use: acute pneumothorax (even if chest drainage is notrequired ); severe chest wall deformities (pectus excavatum, pectus carinatum orpectus arcuatum); severe obesity (BMI >40 kg/m2); pregnancy; thoracic or abdominalsurgery in the six previous weeks
  • Nasal swab positivity to Sars-CoV-2
  • Need for endotracheal intubation or urgent bronchoscopy for excessive airway mucus

Study Design

Total Participants: 88
Study Start date:
December 24, 2022
Estimated Completion Date:
December 24, 2024

Connect with a study center

  • Ospedale San Donato

    Arezzo, AR 52100
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.